HealthcareServices

Glioblastoma Multiforme (GBM) Treatment Industry Poised for Rapid Growth, Forecast to Touch $4.45 Billion by 2030 at 10.2% CAGR

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the glioblastoma multiforme (gbm) treatment market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Glioblastoma Multiforme (GBM) Treatment Market between 2026 and 2030?

The market for glioblastoma multiforme (gbm) treatment has experienced rapid expansion in recent years. This market is set to increase from $2.73 billion in 2025 to $3.02 billion by 2026, achieving a compound annual growth rate (CAGR) of 10.7%. Historically, this growth can be ascribed to factors including limited survival outcomes, a primary reliance on surgery and radiation, the standardization of chemotherapy protocols, the expansion of neuro-oncology centers, and an increase in the diagnosis of brain tumors.

The glioblastoma multiforme (gbm) treatment market size is anticipated to expand significantly in the forthcoming years. It is projected to achieve $4.46 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. This growth during the forecast period is attributable to the progression of targeted therapies, the expansion of immunotherapy pipelines, the adoption of precision medicine, heightened clinical trial activity, and an increase in research funding. Prominent trends throughout this period encompass the escalating embrace of multimodal treatment regimens, more widespread application of tumor treating field therapy, a magnified focus on personalized gbm therapies, the diversification of immunotherapy approaches, and refined post-surgical treatment protocols.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Glioblastoma Multiforme (GBM) Treatment Market?

The expanding occurrence of brain disorders is projected to fuel the advancement of the glioblastoma multiforme (GBM) treatment market in the future. These disorders encompass irregularities in the brain’s function, along with issues affecting nerves located throughout the human body and the spinal cord. The rising incidence of brain disorders, including glioblastoma multiforme (GBM), stems from multiple factors like an aging population, weakened immune systems, excessive diagnoses, exposure to ionizing radiation, and air pollution, among others. Such factors necessitate the treatment of these conditions to enhance overall well-being. For example, data from Dementia Australia, an Australian non-profit organization, indicates that in February 2025, around 433,300 Australians are afflicted with dementia, a figure anticipated to reach 812,500 by 2054. Furthermore, younger-onset dementia impacts approximately 29,000 individuals in 2025, with forecasts suggesting this number will grow to 41,000 by 2054. Consequently, the growing occurrence of brain disorders is a key driver for the expansion of the glioblastoma multiforme (GBM) treatment market.

What Segments Are Included Within The Glioblastoma Multiforme (GBM) Treatment Market?

The glioblastoma multiforme (gbm) treatment market covered in this report is segmented –

1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, R Immunotherapy

2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Surgery: Tumor Resection, Biopsy Procedures

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy

3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens

4) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies

Which Trends Are Shaping Activity Within The Glioblastoma Multiforme (GBM) Treatment Market?

Leading companies within the market are prioritizing the creation of innovative wearable and portable devices to uphold their market presence. These developments aim to furnish users with superior functionality, convenience, and comfort, addressing the increasing demand for accessible and efficient healthcare solutions. For instance, in 2023, Novocure, a Jersey-based oncology company, unveiled Optune Gio, an FDA-approved wearable and portable treatment system for patients with newly diagnosed glioblastoma (GBM). This system applies Tumor Treating Fields (TTFields), which are alternating electric fields that impede cancer cell division, potentially enhancing patient survival. Weighing only 2.7 pounds, Optune Gio is engineered for user comfort, permitting patients to wear it throughout their daily activities.

Who Are The Primary Competitors In The Global Glioblastoma Multiforme (GBM) Treatment Market?

Major companies operating in the glioblastoma multiforme (gbm) treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, Loxo Oncology Inc., Karyopharm Therapeutics Inc., EnGeneIC Ltd., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

Which Regions Are Poised For Strategic Growth In The Glioblastoma Multiforme (GBM) Treatment Market?

North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Glioblastoma Multiforme (GBM) Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8803&type=smp

Browse Through More Reports Similar to the Global Glioblastoma Multiforme (GBM) Treatment Market 2026, By The Business Research Company

Adult Malignant Glioma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Glioblastoma Multiforme Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Glioma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795